Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer carbonate versus placebo for FGF-23 control in non-dialysis chronic kidney disease
2010-020872-49Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Jun 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Renvela with Placebo (2 arms). Primary endpoint: Change in serum C-terminal FGF-23 concentration. Started Jun 2010; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2010-020872-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020872-49.